Starpharma Holdings Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Starpharma Holdings.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	33.6%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Starpharma Holdings no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

CHIA:SPL - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	11	-8	-7	-6	N/A
9/30/2023	7	-12	-10	-10	N/A
6/30/2023	4	-16	-14	-14	N/A
3/31/2023	5	-16	-11	-10	N/A
12/31/2022	5	-16	-8	-7	N/A
9/30/2022	5	-16	-11	-10	N/A
6/30/2022	5	-16	-14	-13	N/A
3/31/2022	5	-17	-18	-17	N/A
12/31/2021	4	-18	-21	-21	N/A
9/30/2021	4	-19	-18	-18	N/A
6/30/2021	3	-20	-15	-15	N/A
3/31/2021	3	-19	-13	-13	N/A
12/31/2020	3	-19	-11	-11	N/A
9/30/2020	5	-17	-11	-11	N/A
6/30/2020	7	-15	-11	-11	N/A
3/31/2020	7	-14	-10	-10	N/A
12/31/2019	8	-13	-8	-8	N/A
9/30/2019	5	-14	-10	-9	N/A
6/30/2019	3	-14	-11	-10	N/A
3/31/2019	4	-13	-9	-8	N/A
12/31/2018	4	-11	-7	-6	N/A
9/30/2018	5	-11	-9	-8	N/A
6/30/2018	5	-10	-11	-10	N/A
3/31/2018	5	-12	N/A	N/A	N/A
12/31/2017	4	-13	-19	-18	N/A
9/30/2017	4	-14	N/A	-18	N/A
6/30/2017	4	-15	N/A	-17	N/A
12/31/2016	1	-20	N/A	-20	N/A
9/30/2016	3	-20	N/A	-19	N/A
6/30/2016	5	-21	N/A	-18	N/A
3/31/2016	5	-22	N/A	-17	N/A
12/31/2015	5	-20	N/A	-16	N/A
9/30/2015	3	-20	N/A	-15	N/A
6/30/2015	2	-19	N/A	-14	N/A
3/31/2015	1	-18	N/A	-11	N/A
12/31/2014	1	-18	N/A	-9	N/A
9/30/2014	1	-16	N/A	-9	N/A
6/30/2014	1	-15	N/A	-10	N/A
3/31/2014	2	-12	N/A	-8	N/A
12/31/2013	2	-9	N/A	-6	N/A
9/30/2013	2	-7	N/A	-8	N/A
6/30/2013	2	-5	N/A	-10	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de SPL es superior a la tasa de ahorro (2.2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de SPL crezcan más rápidamente que el mercado Australian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de SPL crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de SPL crezcan más rápidamente que el mercado de Australian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de SPL crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SPL se prevé que sea elevada dentro de 3 años.

Starpharma Holdings Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.04 loss in FY 2022)

New minor risk - Share price stability

Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer

New minor risk - Market cap size

First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023

Starpharma Holdings Limited Announces Resignation of Nigel Baade as Company Secretary

Starpharma Achieves Marketing Authorization of the Nasal Spray Product, VIRALEZETM, in Indonesia

Starpharma Holdings Limited Announces Positive AZD0466 Clinical Data Presented by Astrazeneca

Starpharma Holdings Limited Announces Management Changes

Starpharma Holdings Limited Launches VIRALEZE in Hong Kong and Macau

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2022

Starpharma Holdings Limited Presents Compelling Data in Prostate Cancer At ESMO

Starpharma Holdings Limited Announces New Clinical Data for Dep Cabazitaxel in Prostate Cancer

Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021)

Starpharma Announces VIRALEZE Protects Against Omicron in Viral Challenge Model

Starpharma Announces SPL7013, the Antiviral Agent in VIRALEZETM Nasal Spray

Starpharma Holdings Limited Appoints Jeff Davies as Director

Starpharma Holdings Limited Announces Relaunch of VIRALEZETM in UK

Starpharma Announces SPL7013 in Viraleze Virucidal Against Omicron

Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Starpharma Holdings Limited Announces Positive Interim Results from Its Ongoing Phase 2 Trial of DEP® Cabazitaxel

Starpharma Announces US Patent and Trademark Office Has Granted New Patent in Relation to DEP® Cabazitaxel

Independent Non-Executive Director recently bought AU$71k worth of stock

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020)

Starpharma Holdings Limited Announces Publication of New Data Demonstrating the Protective Efficacy of VIRALEZETM Antiviral Nasal Spray against SARS-CoV-2 Challenge in Vivo

Independent Non-Executive Deputy Chairman Peter Turvey has left the company

Starpharma Releases New Data About SPL7013

Starpharma Holdings Limited's VIRALEZE Antiviral Nasal Spray Registered for Sale in India

Starpharma Holdings Limited Announces VIRALEZE SPL7013 Highly Active in UK Variant of Coronavirus

Starpharma Announces DEP HER2-Lutetium Outperforms in Human Breast Cancer Model

Starpharma Signs DEP ADC Research Agreement with MSD

Starpharma Holdings Limited Announces AZD0466 Clinical DEP Program Global Expansion

New 90-day high: AU$1.79

New 90-day high: AU$1.66

New 90-day low: AU$1.27

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Announces SPL7013 Shows Potent Antiviral Activity in RSV Expanding Use for Nasal Spray

Starpharma Holdings Limited announced that it has received AUD 45 million in funding

Starpharma Holdings Limited announced that it expects to receive AUD 45 million in funding

Starpharma Holdings Limited Announces That Australia Therapeutic Goods Administration Approves Expansion of the Marketing Authorisation for Vivagel® Bv

New 90-day high - AU$1.73

Earnings released

New 90-day high - AU$1.28

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento